RnRMarketResearch.com adds “Schistosomiasis – Pipeline Review, H1 2015“ report to its research database.
The report “Schistosomiasis – Pipeline Review, H1 2015” provides comprehensive information on the therapeutic development for Schistosomiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schistosomiasis and special features on late-stage and discontinued projects.
Complete Report Details @ http://www.rnrmarketresearch.com/schistosomiasis-pipeline-review-h1-2015-market-report.html .
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Purchase a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=382514 . (This is a premium report priced at US$2000 for a single user License)
Companies discussed in this report includes: BioDiem Ltd, Concert Pharmaceuticals, Inc., Kancera AB, LondonPharma Ltd.
Drugs profiles discussed in this report includes BDM-I, D-Praziquantel, intestinal schistosomiasis vaccine, Small Molecule for Schistosomiasis, Small Molecule for Schistosomiasis,
Featured News & Press Releases:
· Aug 23, 2013: BioDiem US patent for skin and wound infections
· Feb 08, 2013: BioDiem Progresses To Proof-Of-Concept Testing Of BDM-I Antimicrobial Effect Against Parasites
· Nov 08, 2012: BioDiem Partners With Griffith University To Enhance Antimicrobial Drug BDM-I
· Oct 18, 2012: BioDiem Reports Continued Progress In Development Of Antimicrobial BDM-I
· Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I
Table of Contents
List of Tables
Browse more reports on Infectious Diseases Therapeutics @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/infectious-diseases-therapeutics .